Silo Pharma, Inc. announced the filing of a provisional patent application for its lead asset, SPC-15, aimed at treating stress-induced psychiatric disorders such as PTSD. The patent focuses on the ...

Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...

Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a ...

On March 30 the Directive Council of the Portuguese PTMO (INPI) issued decisions 01/2012 and 02/2012 updating their internal procedures on supplementary protection certificates (SPCs), in order to ...

The Court of Justice of the European Union (CJEU) has dealt a blow to innovators in two recent significant judgments, addressing questions posed by national courts struggling to judge the eligibility ...

Pediatric extension is not yet implemented in Norway but will probably be later this year. The instrument is still under discussion within the European Economic Area (EEA) and can only be implemented ...

SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and ...